Thom M H, White P J, Williams R M, Sturdee D W, Paterson M E, Wade-Evans T, Studd J W
Lancet. 1979 Sep 1;2(8140):455-7. doi: 10.1016/s0140-6736(79)91504-6.
The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy. Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen. Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia. 4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy. Cyclical low-dose oestrogen therapy with 7--13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma.
在850名接受雌激素治疗的更年期女性中,对74例患有子宫内膜疾病的患者的治疗方案进行了描述。囊性增生与未加用孕激素的单纯雌激素治疗有关。57例囊性增生患者和8例非典型增生患者中的6例,每日服用5mg炔诺酮,连续21天,共两个疗程,均恢复正常。从其他地方转诊来的4例子宫内膜癌患者显示了不适当且无监督的单纯雌激素治疗所带来的问题,以及区分重度增生与恶性肿瘤的困难。采用7 - 13天孕激素的周期性低剂量雌激素治疗似乎不会增加子宫内膜增生或癌的风险。